FECS-Ad is under clinical development by S.Biomedics and currently in Phase II for Critical Limb Ischemia. According to GlobalData, Phase II drugs for Critical Limb Ischemia does not have sufficient ...
Background: Penetrating craniovertebral junction (CVJ) injuries are rare. The mortality rate of these lesions is extremely high due to the complex anatomy of the region composed of a conglomerate of ...
A new report examines the rise of pre-emptive bans on mandated human microchip implants, noting that 13 states have recently enacted such a ban, despite no companies currently requiring the technology ...